{"id":523876,"date":"2021-08-05T07:05:15","date_gmt":"2021-08-05T11:05:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/"},"modified":"2021-08-05T07:05:15","modified_gmt":"2021-08-05T11:05:15","slug":"vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/","title":{"rendered":"VBL Therapeutics to Report Second Quarter Financial Results on August 16"},"content":{"rendered":"
\n

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT<\/a>) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update.<\/p>\n\n\n\n\n\n\n\n\n\n
\n Conference Call:\u00a0<\/strong>\n <\/td>\n<\/tr>\n
\n Monday, August 16, 2021\u00a0at\u00a08:30am EDT<\/strong>\n <\/td>\n<\/tr>\n
Conference ID: 13721456<\/td>\n\u00a0<\/td>\n<\/tr>\n
US: 1 877 407 9208<\/td>\n\u00a0<\/td>\n<\/tr>\n
Israel Local: 1 809 406 247<\/td>\n\u00a0<\/td>\n<\/tr>\n
International: 1 201 493 6784<\/td>\n\u00a0<\/td>\n<\/tr>\n
Webcast: https:\/\/edge.media-server.com\/mmc\/p\/9trg9snq<\/a><\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About VBL<\/strong>
\n
\n Vascular Biogenics Ltd<\/a>
\n .<\/a>, operating as\u00a0VBL Therapeutics, is a publicly traded (Nasdaq: VBLT<\/a>), clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune- or inflammatory-related indications. The\u00a0VBL Therapeutics\u00a0pipeline has been developed utilizing the company\u2019s three proprietary platform technologies: a gene therapy-based platform technology targeting newly formed blood vessels, an antibody-based technology platform targeting MOSPD2 (motile sperm domain containing 2) and a lecinoxoids platform comprised of a family of small-molecules. The company\u2019s lead oncology candidate, VB-111 (ofranergene obadenovec; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in a phase 3 potential registration trial for platinum-resistant ovarian cancer.<\/p>\n

\n CONTACT:<\/strong>
\n
\n Burns McClellan for VBL Therapeutics<\/strong>
\n
Lee Roth & Eric Ando (Investors)
LRoth@burnsmc.com<\/a> & EAndo@burnsmc.com<\/a>
+1-212-213-0006<\/p>\n

Robert Flamm & Harrison Wong (Media)
RFlamm@burnsmc.com<\/a> & HWong@burnsmc.com<\/a>
<\/a>+1-212-213-0006<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update. Conference Call:\u00a0 Monday, August 16, 2021\u00a0at\u00a08:30am EDT Conference ID: 13721456 \u00a0 US: 1 877 407 9208 \u00a0 Israel Local: 1 809 406 247 \u00a0 International: 1 201 493 6784 \u00a0 Webcast: https:\/\/edge.media-server.com\/mmc\/p\/9trg9snq \u00a0 \u00a0 \u00a0 About VBL Vascular Biogenics Ltd ., operating as\u00a0VBL Therapeutics, is a publicly traded (Nasdaq: VBLT), clinical stage biopharmaceutical … <\/p>\n

Continue reading “VBL Therapeutics to Report Second Quarter Financial Results on August 16”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-523876","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVBL Therapeutics to Report Second Quarter Financial Results on August 16 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VBL Therapeutics to Report Second Quarter Financial Results on August 16 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update. Conference Call:\u00a0 Monday, August 16, 2021\u00a0at\u00a08:30am EDT Conference ID: 13721456 \u00a0 US: 1 877 407 9208 \u00a0 Israel Local: 1 809 406 247 \u00a0 International: 1 201 493 6784 \u00a0 Webcast: https:\/\/edge.media-server.com\/mmc\/p\/9trg9snq \u00a0 \u00a0 \u00a0 About VBL Vascular Biogenics Ltd ., operating as\u00a0VBL Therapeutics, is a publicly traded (Nasdaq: VBLT), clinical stage biopharmaceutical … Continue reading "VBL Therapeutics to Report Second Quarter Financial Results on August 16"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T11:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VBL Therapeutics to Report Second Quarter Financial Results on August 16\",\"datePublished\":\"2021-08-05T11:05:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/\"},\"wordCount\":262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/\",\"name\":\"VBL Therapeutics to Report Second Quarter Financial Results on August 16 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=\",\"datePublished\":\"2021-08-05T11:05:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VBL Therapeutics to Report Second Quarter Financial Results on August 16\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VBL Therapeutics to Report Second Quarter Financial Results on August 16 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/","og_locale":"en_US","og_type":"article","og_title":"VBL Therapeutics to Report Second Quarter Financial Results on August 16 - Market Newsdesk","og_description":"TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update. Conference Call:\u00a0 Monday, August 16, 2021\u00a0at\u00a08:30am EDT Conference ID: 13721456 \u00a0 US: 1 877 407 9208 \u00a0 Israel Local: 1 809 406 247 \u00a0 International: 1 201 493 6784 \u00a0 Webcast: https:\/\/edge.media-server.com\/mmc\/p\/9trg9snq \u00a0 \u00a0 \u00a0 About VBL Vascular Biogenics Ltd ., operating as\u00a0VBL Therapeutics, is a publicly traded (Nasdaq: VBLT), clinical stage biopharmaceutical … Continue reading \"VBL Therapeutics to Report Second Quarter Financial Results on August 16\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-05T11:05:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VBL Therapeutics to Report Second Quarter Financial Results on August 16","datePublished":"2021-08-05T11:05:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/"},"wordCount":262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/","name":"VBL Therapeutics to Report Second Quarter Financial Results on August 16 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=","datePublished":"2021-08-05T11:05:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMjE1MSM0MzM5MjUzIzIwMDE0MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vbl-therapeutics-to-report-second-quarter-financial-results-on-august-16\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VBL Therapeutics to Report Second Quarter Financial Results on August 16"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=523876"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/523876\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=523876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=523876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=523876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}